BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,088 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
HARTFORD INVESTMENT MANAGEMENT CO 55,289$4,446,0000.15%
FIRST UNITED BANK & TRUST 3,357$270,0000.15%
Wealth Architects, LLC 6,865$552,0000.15%
Realta Investment Advisors 5,483$441,0000.15%
Kentucky Retirement Systems Insurance Trust Fund 13,280$1,068,0000.15%
Financial Advisory Group 5,694$458,0000.15%
Institute for Wealth Management, LLC. 8,033$646,0000.15%
BRADLEY FOSTER & SARGENT INC/CT 62,436$5,021,0000.15%
Paragon Capital Management Ltd 3,361$270,0000.15%
Kentucky Retirement Systems 29,547$2,376,0000.15%
AGF Investments LLC 16,297$1,311,0000.15%
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY 159,622$12,837,0000.15%
LEO BROKERAGE, LLC 4,060$350,0000.14%
ExodusPoint Capital Management, LP 90,625$7,288,0000.14%
WHITE PINE CAPITAL LLC 4,400$354,0000.14%
Perigon Wealth Management, LLC 12,811$1,030,0000.14%
NORTHERN TRUST CORP 8,168,239$656,888,0000.14%
FORSTA AP-FONDEN 86,800$6,980,0000.14%
AR ASSET MANAGEMENT INC 5,106$411,0000.14%
Magnetar Financial LLC 100,355$8,071,0000.14%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.